Subscribe To
GBT / See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
GBT News
By The Motley Fool
August 8, 2022
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion. more_horizontal
By Market Watch
August 4, 2022
Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'
Shares of Global Blood Therapeutics Inc. GBT, +3.04% were up 34.4% in premarket trading on Thursday after Bloomberg reported that the company is "attr more_horizontal
By Seeking Alpha
June 21, 2022
Global Blood Therapeutics: Powerhouse Of The Future
In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth du more_horizontal
By Seeking Alpha
May 4, 2022
Global Blood Therapeutics Inc. (GBT) CEO Ted Love on Q1 2022 Results - Earnings Call Transcript
Global Blood Therapeutics, Inc. (NASDAQ:GBT ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Steven Immergut – Senior more_horizontal
By Zacks Investment Research
May 4, 2022
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold cl more_horizontal
By Seeking Alpha
April 12, 2022
Global Blood Therapeutics: Hitting A Growth Inflection
Global Blood Therapeutics: Hitting A Growth Inflection more_horizontal
By Zacks Investment Research
March 25, 2022
Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Seeking Alpha
March 12, 2022
Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Global Blood Therapeutics: Changing My Strategy After Recent Earnings more_horizontal